Copyright
©The Author(s) 2015.
World J Stem Cells. Aug 26, 2015; 7(7): 1022-1038
Published online Aug 26, 2015. doi: 10.4252/wjsc.v7.i7.1022
Published online Aug 26, 2015. doi: 10.4252/wjsc.v7.i7.1022
Table 1 Ongoing clinical trials recruiting patients with acute leukemia
Clinical trial.govID | Center | Disease | Antigen (scFv) | CAR signaling domain | Vector | Transplantation history | Origin | Lymphocyte depletion | Patients age |
Acute lymphoid malignancies | |||||||||
NCT01044069 | MSKCC | B-ALL | CD19 | CD3ζ-CD28 | γ-retrovirus | Autologous | Autologous | Chemo | ≥ 18 yr |
NCT01860937 | MSKCC | B-ALL | CD19 | CD3ζ-CD28 | γ-retrovirus | Autologous | Autologous | Cy | up to 26 yr |
NCT01430390 | MSKCC | B-ALL | CD19 VST (EBV) | CD3ζ | Lentivirus | Relapse post-ASCT | Allogenic | Chemo | up to 19 yr |
NCT01626495 | CHOP | B-ALL | CD19 | CD3ζ-4-1BB vs CD3ζ | Lentivirus | Relapse after ASCT | Autologous | Chemo | 1-24 yr |
NCT02030847 | University of Pennsylvania | B-ALL | CD19 | CD3ζ-4-1BB | Lentivirus | Relapse ± after ASCT | Autologous | NS | ≥ 18 yr |
NCT00840853 | BCM | B-ALL/NHL/CLL | CD19 VST (EBV) | CD3ζ | γ-retrovirus | Post-ASCT | Allogenic | No | No limit |
NCT00586391 | BCM | B-ALL/NHL/CLL | CD19 | CD3ζ-CD28 | γ-retrovirus | No ASCT | Autologous | NS | ≥ 18 yr |
NCT02132624 (not open) | Uppsala University | B-ALL/NHL | CD19 | CD3ζ-4-1BB-CD28 | γ-retrovirus | Relapse ± after ASCT | Autologous | NS | ≥ 18 yr |
NCT01593696 | NCI | B-ALL/NHL/CLL | CD19 | CD3ζ | γ-retrovirus | Relapse ± after ASCT | Autologous | Flu/Cy | 1-30 yr |
NCT01087294 | NCI | B-ALL/NHL/CLL | CD19 VST (EBV) | CD3ζ | γ-retrovirus | Relapse post-ASCT | Allogenic | Cy | 18-75 yr |
NCT01683279 | Seattle Children Hospital | B-ALL | CD19 EGFRt+ | CD3ζ-CD28 | Lentivirus | No ASCT | Autologous | Cy | 1-26 yr |
NCT02028455 | Seattle Children Hospital | B-ALL | CD19 EGFRt+ | CD3ζ-4-1BB | Lentivirus | Relapse after ASCT vs no ASCT | Autologous | Cy/Flu/TBI | 1-26 yr |
NCT01865617 | FHCRC | B-ALL/NHL/CLL | CD19 | CD3ζ | Lentivirus | > 1st relapse | Autologous | NS | ≥ 18 yr |
NCT01475058 | FHCRC | B-ALL/NHL/CLL | CD19 VST (CMV, EBV) | CD3ζ | Lentivirus | Post-ASCT | Allogenic | No | 18-75 yr |
NCT02051257 | City of Hope Medical Center | B-ALL/NHL/CLL | CD19 EGFRt+ | CD3ζ-CD28 | Lentivirus | Post-ASCT | Autologous | Chemo | ≥ 18 yr |
NCT02146924 (not open) | City of Hope Medical Center | B-ALL | CD19 EGFRt+ | CD3ζ-CD28 | Lentivirus | Relapse/progression ± after ASCT | Autologous | Cy | ≥ 18 yr |
NCT01195480 | London University College | B-ALL | CD19 (EBV-CTL) | CD3ζ | γ-retrovirus | Relapse after 1st ASCT | Allogenic | NS | Up to 18 yr |
NCT01864889 | Chinese PLA General Hospital | B-ALL/NHL/CLL | CD19 | CD3ζ-4-1BB vs CD3ζ | γ-retrovirus | Relapse ± after ASCT | Autologous | NS | 5-90 yr |
NCT01735604 | Chinese PLA General Hospital | B-ALL/NHL/CLL | CD20 | CD3ζ-4-1BB vs CD3ζ | γ-retrovirus | Relapse ± after ASCT | Autologous | NS | 18-90 yr |
NCT01362452 | MDACC | B-ALL/NHL/CLL | CD19 (cord blood derived) | CD3ζ | Transposon | Relapse post-ASCT | Allogenic | No | 1-75 yr |
NCT01497184 | MDACC | B-ALL/NHL/CLL | CD19 | CD3ζ | Transposon | Post-ASCT | Allogenic | No | 1-65 yr |
Acute myeloid malignancies | |||||||||
NCT01864902 | Chinese PLA General Hospital | AML | CD33 | CD3ζ-4-1BB vs CD3ζ | γ-retrovirus | Relapse ± after ASCT | Autologous/ Allogenic | NS | 5-90 yr |
NCT02159495 | City of Hope Medical Center | AML | CD123 EGFRt+ | CD3ζ-CD28 | γ-retrovirus | Relapse/refractory AML | Autologous | Cy | ≥ 18 yr |
- Citation: Heiblig M, Elhamri M, Michallet M, Thomas X. Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015; 7(7): 1022-1038
- URL: https://www.wjgnet.com/1948-0210/full/v7/i7/1022.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v7.i7.1022